然而,近年来,有一批HER2表达水平低(HER2-low)的乳腺癌患者引起了研究者的关注。这部分患者的HER2水平介于HER2阴性和HER2过表达之间,他们的治疗和预后一直不明确。2023年4月,Breast Cancer Research and Treatment杂志发表了一篇题为HER-2 ...
目前,HER2 低表 达乳腺癌的生物学特征尚不十分明确,HER2 低表达与 HER2 零表达患者预后以及传统治疗 反应差异亦不明确。该研究旨在明确 HER2 低表达与 HER2 零表达早期乳腺癌(eBC)患者 新辅助化疗(NAC)后的化疗敏感性和长期预后。 研...
Find information about Herceptin® (trastuzumab), a treatment for HER2+ early and metastatic breast cancer and stomach cancer/GEJ. See full safety & Boxed Warnings for more information.
We developed and prepared a tandem, single-chain, variable fragment Fc fusion protein [tandem single-chain variable fragment (scFv) Fc fusion protein] that is reactive to both human epidermal growth factor receptor 2 (Her2) ...
Impact of ADC Toxicities and Clinical Decision-Making for mBC Dr Jain on Existing Challenges Within the TNBC Treatment Paradigm SABCS Highlights and Future Directions in the Treatment of Breast Cancer Emerging Frontline, Adjuvant, and Neoadjuvant Strategies with T-DXd in HER2+ Breast Cancer...
为探究乳腺癌脑转移(BCBMs)治疗策略变化对患者结局的影响,意大利和法国多家机构研究人员开展相关研究。结果发现仅 HR-/HER2 + 患者总生存期改善。该研究对优化治疗、评估预后意义重大,值得科研读者一读。 在女性健康领域,乳腺癌(Breast Cancer,BC)就像一个 “难缠的敌人”,它是全球女性中最常见的癌症,也是癌症相关...
use prior to surgery (neoadjuvant treatment) in people with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (tumor is greater than 2 cm in diameter or node-positive). PERJETA should be used as part of a complete treatment regimen for early breast cancer. ...
the neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node-positive) as part of a complete treatment regimen for early breast cancer (EBC) the adjuvant treatment of patients with HER2-positive...
(trastuzumab emtansine) plus or minus tucatinib in patients with HER2-positive breast cancer. The results demonstrated a significant improvement in median progression-free survival, especially in the subset with brain metastases. The trial’s unique aspects include a diverse patient population with ...
Ref:2017 Lancet Breast cancer 四种原始亚型既可以通过多基因检测直接确定,也可以通过免疫组化间接检测类固醇激素受体(雌激素受体[ER] ,孕酮受体 [PgR] 和HER2 ,以及通过 Ki67测量的肿瘤增殖如下:管腔A 样亚型(ER或 PgR阳性,或两者,HER2 阴性,低增殖);管腔B 样亚型(ER或 PgR...